Raymond James & Associates lowered its position in Haemonetics Co. (NYSE:HAE – Get Rating) by 58.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,154 shares of the medical instruments supplier’s stock after selling 17,104 shares during the quarter. Raymond James & Associates’ holdings in Haemonetics were worth $900,000 as of its most recent filing with the Securities and Exchange Commission.
→ The Next Big Crisis Is Here (From Porter & Company)
Several other large investors also recently made changes to their positions in HAE. USA Financial Portformulas Corp acquired a new position in shares of Haemonetics during the third quarter valued at approximately $91,000. Cardinal Capital Management increased its stake in shares of Haemonetics by 3.3% during the third quarter. Cardinal Capital Management now owns 10,542 shares of the medical instruments supplier’s stock valued at $780,000 after acquiring an additional 337 shares during the period. FinTrust Capital Advisors LLC acquired a new position in shares of Haemonetics during the third quarter valued at approximately $60,000. Louisiana State Employees Retirement System acquired a new position in shares of Haemonetics during the third quarter valued at approximately $1,014,000. Finally, Boston Trust Walden Corp increased its stake in shares of Haemonetics by 3.4% during the third quarter. Boston Trust Walden Corp now owns 628,825 shares of the medical instruments supplier’s stock valued at $46,552,000 after acquiring an additional 20,849 shares during the period.
Haemonetics Stock Down 3.1 %
NYSE:HAE opened at $85.18 on Friday. The firm has a market capitalization of $4.31 billion, a price-to-earnings ratio of 51.31 and a beta of 0.39. Haemonetics Co. has a 1-year low of $43.50 and a 1-year high of $91.39. The company has a current ratio of 2.73, a quick ratio of 1.76 and a debt-to-equity ratio of 1.04. The business’s fifty day moving average price is $82.12 and its 200 day moving average price is $77.58.
Haemonetics (NYSE:HAE – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The medical instruments supplier reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.13. The firm had revenue of $297.49 million for the quarter, compared to analyst estimates of $273.92 million. Haemonetics had a return on equity of 20.05% and a net margin of 7.94%. On average, sell-side analysts forecast that Haemonetics Co. will post 2.87 earnings per share for the current fiscal year.
Insider Activity at Haemonetics
In related news, EVP Josep Llorens sold 2,391 shares of the company’s stock in a transaction on Monday, January 23rd. The stock was sold at an average price of $90.00, for a total transaction of $215,190.00. Following the transaction, the executive vice president now directly owns 17,234 shares of the company’s stock, valued at $1,551,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.65% of the stock is owned by insiders.
Analyst Ratings Changes
A number of research firms recently commented on HAE. Mizuho raised their price objective on shares of Haemonetics from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, January 24th. TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b” rating in a research report on Monday, November 7th. JMP Securities lifted their price target on shares of Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 8th. Citigroup lifted their price target on shares of Haemonetics from $88.00 to $92.00 and gave the stock a “neutral” rating in a research report on Monday, December 12th. Finally, Morgan Stanley decreased their price target on shares of Haemonetics from $90.00 to $84.00 and set an “equal weight” rating on the stock in a research report on Friday, January 6th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.50.
About Haemonetics
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
Featured Articles
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Haemonetics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Haemonetics wasn’t on the list.
While Haemonetics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
